A review of vinorelbine in the treatment of breast cancer

G. H. Domenech, Charles Vogel

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

As combinations and sequences of anthracyclines and taxanes increasingly become standard adjuvant treatment for early breast cancer, a major need for new treatment options for metastatic breast cancer will arise. Vinorelbine is highly active in the treatment of metastatic breast cancer, both as a single agent and in combination regimens. Furthermore, it is well tolerated, with a low incidence of subjective toxicities. It is anticipated, therefore, that vinorelbine will become increasingly utilized for treating metastatic breast cancer due to its favorable safety profile, good tolerability, and promising results in combination with other chemotherapy agents. Combinations with trastuzumab and newer molecular targeting agents are being explored. Doublets or triplets of vinorelbine with drugs other than anthracyclines and taxanes could be considered in the next generation of adjuvant and neoadjuvant trials, where it is anticipated that anthracycline/taxane combinations are likely to replace anthracycline/cyclophosphamide combinations as the mainstay of adjuvant treatment.

Original languageEnglish
Pages (from-to)113-128
Number of pages16
JournalClinical Breast Cancer
Volume2
Issue number2
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

Anthracyclines
Breast Neoplasms
Taxoids
Therapeutics
Cyclophosphamide
Safety
Drug Therapy
vinorelbine
Incidence
Pharmaceutical Preparations

Keywords

  • Adjuvant therapy
  • Combination therapy
  • Doxorubicin
  • Fluoropyrimidines
  • Taxanes
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research

Cite this

A review of vinorelbine in the treatment of breast cancer. / Domenech, G. H.; Vogel, Charles.

In: Clinical Breast Cancer, Vol. 2, No. 2, 01.01.2001, p. 113-128.

Research output: Contribution to journalArticle

@article{37c4fd2112e940c98642a0843b0b0915,
title = "A review of vinorelbine in the treatment of breast cancer",
abstract = "As combinations and sequences of anthracyclines and taxanes increasingly become standard adjuvant treatment for early breast cancer, a major need for new treatment options for metastatic breast cancer will arise. Vinorelbine is highly active in the treatment of metastatic breast cancer, both as a single agent and in combination regimens. Furthermore, it is well tolerated, with a low incidence of subjective toxicities. It is anticipated, therefore, that vinorelbine will become increasingly utilized for treating metastatic breast cancer due to its favorable safety profile, good tolerability, and promising results in combination with other chemotherapy agents. Combinations with trastuzumab and newer molecular targeting agents are being explored. Doublets or triplets of vinorelbine with drugs other than anthracyclines and taxanes could be considered in the next generation of adjuvant and neoadjuvant trials, where it is anticipated that anthracycline/taxane combinations are likely to replace anthracycline/cyclophosphamide combinations as the mainstay of adjuvant treatment.",
keywords = "Adjuvant therapy, Combination therapy, Doxorubicin, Fluoropyrimidines, Taxanes, Vinorelbine",
author = "Domenech, {G. H.} and Charles Vogel",
year = "2001",
month = "1",
day = "1",
language = "English",
volume = "2",
pages = "113--128",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - A review of vinorelbine in the treatment of breast cancer

AU - Domenech, G. H.

AU - Vogel, Charles

PY - 2001/1/1

Y1 - 2001/1/1

N2 - As combinations and sequences of anthracyclines and taxanes increasingly become standard adjuvant treatment for early breast cancer, a major need for new treatment options for metastatic breast cancer will arise. Vinorelbine is highly active in the treatment of metastatic breast cancer, both as a single agent and in combination regimens. Furthermore, it is well tolerated, with a low incidence of subjective toxicities. It is anticipated, therefore, that vinorelbine will become increasingly utilized for treating metastatic breast cancer due to its favorable safety profile, good tolerability, and promising results in combination with other chemotherapy agents. Combinations with trastuzumab and newer molecular targeting agents are being explored. Doublets or triplets of vinorelbine with drugs other than anthracyclines and taxanes could be considered in the next generation of adjuvant and neoadjuvant trials, where it is anticipated that anthracycline/taxane combinations are likely to replace anthracycline/cyclophosphamide combinations as the mainstay of adjuvant treatment.

AB - As combinations and sequences of anthracyclines and taxanes increasingly become standard adjuvant treatment for early breast cancer, a major need for new treatment options for metastatic breast cancer will arise. Vinorelbine is highly active in the treatment of metastatic breast cancer, both as a single agent and in combination regimens. Furthermore, it is well tolerated, with a low incidence of subjective toxicities. It is anticipated, therefore, that vinorelbine will become increasingly utilized for treating metastatic breast cancer due to its favorable safety profile, good tolerability, and promising results in combination with other chemotherapy agents. Combinations with trastuzumab and newer molecular targeting agents are being explored. Doublets or triplets of vinorelbine with drugs other than anthracyclines and taxanes could be considered in the next generation of adjuvant and neoadjuvant trials, where it is anticipated that anthracycline/taxane combinations are likely to replace anthracycline/cyclophosphamide combinations as the mainstay of adjuvant treatment.

KW - Adjuvant therapy

KW - Combination therapy

KW - Doxorubicin

KW - Fluoropyrimidines

KW - Taxanes

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0034887732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034887732&partnerID=8YFLogxK

M3 - Article

C2 - 11899783

AN - SCOPUS:0034887732

VL - 2

SP - 113

EP - 128

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 2

ER -